Review
Oncology
Samia Asif, Benjamin A. Teply
Summary: Prostate cancer is a leading cause of cancer-related death among males, and despite many available treatments, advanced prostate cancer remains incurable and fatal. Personalized treatment and the use of biomarkers for decision-making are crucial for optimizing clinical outcomes in managing advanced prostate cancer.
Review
Medicine, General & Internal
Ciara S. McNevin, Anne-Marie Baird, Ray McDermott, Stephen P. Finn
Summary: Prostate Cancer is a leading cause of morbidity and mortality among men worldwide. Advanced PCa patients have seen improved survival outcomes in the last decade with new therapeutic options, but there is still a high rate of death associated with this stage. The lack of strong evidence guiding the timing and sequence of novel treatment strategies remains a challenge.
Review
Biotechnology & Applied Microbiology
Bin Hao, Li Wei, Yusheng Cheng, Zhifang Ma, Jingyu Wang
Summary: Prostate cancer is the second most common cancer in men globally. Early diagnosis is crucial due to the lack of obvious symptoms in the early stage. Highly sensitive and precise diagnostic methods, as well as targeted therapy regimens, play key roles in the treatment of prostate cancer.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Article
Oncology
Megan E. V. Caram, Jennifer Burns, Kyle Kumbier, Jordan B. Sparks, Phoebe A. Tsao, Christina H. Chapman, Jordan Bauman, Brent K. Hollenbeck, Vahakn B. Shahinian, Ted A. Skolarus
Summary: This study evaluated clinical and nonclinical factors associated with first-line treatment for metastatic castration-resistant prostate cancer in a national delivery system. Results showed that age, preexisting comorbidities, and PSA values influenced the treatment selection, while race may also play a role in the receipt of guideline-discordant treatment.
Review
Pharmacology & Pharmacy
Sonia Vicente-Ruiz, Antoni Serrano-Marti, Ana Arminan, Maria J. Vicent
Summary: Current treatment options for advanced prostate cancer, such as hormonal therapy, chemotherapy, immunotherapy, and radiotherapy, lack targeting and efficiency. Using nanomedicine approaches can improve stability, tumor targeting, and pharmacokinetics to enhance patient outcomes. Research is ongoing to enhance passive accumulation of nanomedicines in tumors and explore combination therapies for more effective treatment.
ADVANCED THERAPEUTICS
(2021)
Editorial Material
Medicine, General & Internal
Hanna K. Sanoff
Summary: The cure rate for nonmetastatic rectal cancer has been improving over the years, with surgery, radiation therapy, and chemotherapy being the routine treatment. Recent studies have shown that adding multiagent chemotherapy to radiation therapy before proctectomy can significantly increase the 3-year disease-free survival rate. However, this treatment approach also comes with severe long-term sequelae.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Xianrui Han, Cameron Armstrong, Wei Lou, Alan P. Lombard, Chengfei Liu, Allen C. Gao
Summary: Treatment resistance is a common challenge in castration-resistant prostate cancer. This study examines the resistance patterns of different therapeutic classes and emphasizes the importance of rational drug sequencing in treatment. The findings reveal distinct cross-resistance characteristics among different resistant cell sublines and provide insights into the underlying mechanisms of resistance.
Review
Oncology
Tomoyuki Makino, Kouji Izumi, Hiroaki Iwamoto, Atsushi Mizokami
Summary: The definitions and treatments of very high-risk prostate cancer and oligometastatic prostate cancer remain challenging, with multidisciplinary treatment showing promise but lacking a standard approach.
Review
Oncology
Hao Liang, Yang Liu, Jiao Guo, Maoyang Dou, Xiaoyi Zhang, Liyong Hu, Jun Chen
Summary: Prostate cancer is a common malignant cancer of the male genitourinary system. Immunotherapy has shown initial success in the treatment of advanced prostate cancer.
FRONTIERS IN ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
Soghra Bagheri, Mahdie Rahban, Fatemeh Bostanian, Fatemeh Esmaeilzadeh, Arash Bagherabadi, Samaneh Zolghadri, Agata Stanek
Summary: Prostate cancer, when it spreads to the bone, is known as metastatic bone cancer. Currently, effective treatment options are still lacking for advanced/metastatic PC. However, understanding the molecular events that contribute to PC progression provides hope for the development of new treatment strategies. Protein kinases play crucial roles in the growth, proliferation, and metastases of prostatic tumors, making combinatorial therapy with PK inhibitors a potential treatment approach. Additionally, epigenetic pathways are also involved in PC, suggesting another potential combination treatment strategy.
Review
Oncology
Verane Achard, Cedric Michael Panje, Daniel Engeler, Thomas Zilli, Paul Martin Putora
Summary: Treatment options for localized and locally advanced prostate cancer include active surveillance, radiotherapy, surgery, and androgen deprivation therapy, depending on the risk level of disease recurrence. Prioritizing patients' choice based on logistics and the toxicity profile of each option is crucial for achieving good overall survival rates.
Review
Oncology
Tanya B. Dorff, Vivek Narayan, Stephen J. Forman, Peter D. Zang, Joseph A. Fraietta, Carl H. June, Naomi B. Haas, Saul J. Priceman
Summary: Immunotherapy has not achieved long-lasting remissions in advanced prostate cancer patients. More potent T-cell redirecting strategies are needed to overcome the immunologically exclusive and suppressive tumor microenvironment. This review provides an in-depth perspective on the various immunotherapy strategies currently under clinical investigation for men with advanced prostate cancer.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
David H. Howard, Ruben G. W. Quek, Kathleen M. Fox, Bhakti Arondekar, Christopher P. Filson
Summary: The study evaluated the real-world effectiveness and value of drugs recently approved for advanced prostate cancer. Between 2007-2009 and 2014-2016, life expectancy increased by 12.6 months and lifetime medical costs increased by $87,000.
Article
Chemistry, Medicinal
Davide Moi, Davide Bonanni, Silvia Belluti, Pasquale Linciano, Andrea Citarella, Silvia Franchini, Claudia Sorbi, Carol Imbriano, Luca Pinzi, Giulio Rastelli
Summary: In this study, new HDAC inhibitors were designed, synthesized and tested, showing nanomolar inhibitory activity against HDAC6. Compounds of the trifluoromethyloxadiazole and hydroxamic acid series exhibited promising anti-proliferative activities and HDAC6 targeting in PCA cells. Compound 13, which showed potent inhibitory activity and class II selectivity along with favorable drug-like properties, demonstrated excellent anti-proliferative activity and marked anti-migration properties on PCA cells.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Oncology
A. Gonzalez del Alba, M. J. Mendez-Vidal, S. Vazquez, E. Castro, M. A. Climent, E. Gallardo, E. Gonzalez-Billalabeitia, D. Lorente, J. P. Maroto, J. A. Arranz
Summary: Recent advances in molecular research and new drug development have led to the evolution of advanced prostate cancer treatment. Individualized therapies can be selected based on dynamic aberrations in key pathways such as the androgen receptor, DNA repair genes, and PTEN-PI3K. Testing for specific genetic mutations like BRCA1 and BRCA2 is recommended, with a combination of treatments like castration, chemotherapy, and targeted therapies providing better outcomes for different patient populations.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)